Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.33 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.33 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.33 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776702 | 0.85 | HRH3 (0.41) | DRD2DRD4HRH3APPS1PR1 | |
| SCHEMBL2777158 | 0.80 | DRD2 (0.43) | DRD2DRD4HRH3APPPIK3CD | |
| SCHEMBL2777117 | 0.77 | MEN1 (0.56) | DRD2DRD4HRH3PIK3CDMAOA | |
| SCHEMBL2776946 | 0.77 | HRH3 (0.44) | HRH3GAAHTTCA12CA1 | |
| SCHEMBL14553221 | 0.74 | HRH3 (0.44) | DRD2DRD4HRH3APPMAOA | |
| SCHEMBL2777149 | 0.74 | HRH3 (0.41) | DRD2DRD4HRH3APPMAOA | |
| SCHEMBL3183236 | 0.73 | DRD2 (0.47) | DRD2DRD4HRH3APPMAOA | |
| SCHEMBL23143495 | 0.72 | EIF2AK2 (0.62) | MAOAMAOBS1PR1PLAAT3PLAAT5 | |
| SCHEMBL12972302 | 0.72 | RAB9A (0.51) | DRD2DRD4HRH3APP | |
| SCHEMBL29899588 | 0.72 | EIF2AK2 (0.62) | MAOAMAOBS1PR1PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | DRD2 3657/4885DRD4 4319/4885HRH3 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.